Diabetes Research and Clinical Practice
Volume 77, Issue 3 , Pages 414-419 , September 2007

Correlations of urinary albumin excretion and atherosclerosis in Japanese type 2 diabetic patients

  • Futoshi Anan

      Affiliations

    • Department of Cardiology, Oita Red Cross Hospital, Oita, Japan
    • First Department of Internal Medicine, School of Medicine, Oita University, Oita, Japan
    • Corresponding Author InformationCorresponding author at: Department of Cardiology, Oita Red Cross Hospital, 3-2-37 Chiyomachi, Oita 870-0033, Japan. Tel.: +81 97 532 6181; fax: +81 97 533 1207.
    • ,
  • Takayuki Masaki

      Affiliations

    • First Department of Internal Medicine, School of Medicine, Oita University, Oita, Japan
    • ,
  • Yoshikazu Umeno

      Affiliations

    • Department of Internal Medicine, Oita Red Cross Hospital, Oita, Japan
    • ,
  • Naoya Fukunaga

      Affiliations

    • Department of Cardiology, Oita Red Cross Hospital, Oita, Japan
    • ,
  • Yasushi Teshima

      Affiliations

    • Department of Cardiology, Oita Red Cross Hospital, Oita, Japan
    • ,
  • Tetsu Iwao

      Affiliations

    • Department of Cardiology, Oita Red Cross Hospital, Oita, Japan
    • ,
  • Koji Kaneda

      Affiliations

    • Department of Cardiology, Oita Red Cross Hospital, Oita, Japan
    • ,
  • Hidetoshi Yonemochi

      Affiliations

    • Department of Cardiovascular Science, School of Medicine, Oita University, Oita, Japan
    • ,
  • Nobuoki Eshima

      Affiliations

    • Department of Biostatistics, School of Medicine, Oita University, Oita, Japan
    • ,
  • Tetsunori Saikawa

      Affiliations

    • Department of Cardiovascular Science, School of Medicine, Oita University, Oita, Japan
    • ,
  • Hironobu Yoshimatsu

      Affiliations

    • First Department of Internal Medicine, School of Medicine, Oita University, Oita, Japan

Received 30 August 2006 ,Revised 22 December 2006 ,Accepted 4 January 2007.

References 

  1. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care. 1993;16:434–444
  2. Mogensen CE. Microalbuminuria, blood pressure and diabetic renal disease: origin and development of ideas. Diabetologia. 1999;42:263–285
  3. Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA. 2001;286:421–426
  4. de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation. 2004;110:921–927
  5. Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, Jensen T, Kofoed-Enevoldsen A. Albuminuria reflects widespread vascular damage. The Steno hypothesis. Diabetologia. 1989;32:219–226
  6. Stehouwer CD, Nauta JJ, Zeldenrust GC, Hackeng WH, Donker AJ, den Ottolander GJ. Urinary albumin excretion, cardiovascular disease, and endothelial dysfunction in non-insulin-dependent diabetes mellitus. Lancet. 1992;340:319–323
  7. Cruickshank K, Riste L, Anderson SG, Wright JS, Dunn G, Gosling RG. Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance: an integrated index of vascular function?. Circulation. 2002;106:2085–2090
  8. Reaven GM. Role of insulin resistance in human disease. Diabetes. 1988;37:1595–1607
  9. DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care. 1991;14:173–194
  10. Zureik M, Bureau JM, Temmar M, Adamopoulos C, Courbon D, Bean K, et al. Echogenic carotid plaques are associated with aortic arterial stiffness in subjects with subclinical carotid atherosclerosis. Hypertension. 2003;41:519–527
  11. Laurent S, Boutouyrie P, Asmar R, Gautier I, Laloux B, Guize L, et al. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension. 2001;37:1236–1241
  12. Tomiyama H, Yamashina A, Arai T, Hirose K, Koji Y, Chikamori T, et al. Influences of age and gender on results of noninvasive brachial-ankle pulse wave velocity measurement-a survey of 12517 subjects. Atherosclerosis. 2003;166:303–309
  13. Yamashina A, Tomiyama H, Arai T, Hirose K, Koji Y, Hirayama Y, et al. Brachial-ankle pulse wave velocity as a marker of atherosclerotic vascular damage and cardiovascular risk. Hypertens. Res. 2003;26:615–622
  14. Yamashina A, Tomiyama H, Takeda K, Tsuda H, Arai T, Hirose K, et al. Validity, reproducibility, and clinical significance of noninvasive brachial-ankle pulse wave velocity measurement. Hypertens. Res. 2002;25:359–364
  15. Tomiyama H, Koji Y, Yambe M, Shiina K, Motobe K, Yamada J, et al. Brachial-ankle pulse wave velocity is a simple and independent predictor of prognosis in patients with acute coronary syndrome. Circ. J. 2005;69:815–822
  16. Liao D, Sloan RP, Cascio WE, Folsom AR, Liese AD, Evans GW, et al. Multiple metabolic syndrome is associated with lower heart rate variability. The atherosclerosis risk in communities study. Diabetes Care. 1998;21:2116–2122
  17. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–419
  18. Goligorsky MS, Chen J, Brodsky S. Endothelial cell dysfunction leading to diabetic nephropathy: focus on nitric oxide. Hypertension. 2001;37:412–419
  19. Gutterman DD. Vascular dysfunction in hyperglycemia: is protein kinase C the culprit?. Circ. Res. 2002;90:5–7
  20. Stout RW. Insulin and atheroma: 20-yr perspective. Diabetes Care. 1990;13:631–654
  21. Kuboki K, Jiang ZY, Takahara N, Ha SW, Igarashi M, Yamauchi T, et al. Regulation of endothelial constitutive nitric oxide synthase gene expression in endothelial cells and in vivo: a specific vascular action of insulin. Circulation. 2000;101:676–681
  22. Steinberg HO, Paradisi G, Hook G, Crowder K, Cronin J, Baron AD. Free fatty acid elevation impairs insulin-mediated vasodilation and nitric oxide production. Diabetes. 2000;49:1231–1238
  23. Arcaro G, Gretti A, Balzano S, Lechi A, Muggeo M, Bonora E, et al. Insulin causes endothelial dysfunction in humans: sites and mechanisms. Circulation. 2002;105:576–582
  24. Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G, Baron AD. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J. Clin. Invest. 1996;97:2601–2610
  25. Hu CT, Dinenno FA, Monahan KD, Chen HI. Acute effects of nitric oxide blockade with L-NAME on arterial haemodynamics in the rat. Br. J. Pharmacol. 1997;122:1237–1243
  26. Indolfi C, Torella D, Cavuto L, Davalli AM, Coppola C, Esposito G, et al. Effects of balloon injury on neointimal hyperplasia in streptozotocin-induced diabetes and in hyperinsulinemic nondiabetic pancreatic islet-transplanted rats. Circulation. 2001;103:2980–2986
  27. Lender D, Arauz-Pacheco C, Breen L, Mora-Mora P, Ramirez LC, Raskin P. A double blind comparison of the effects of amlodipine and enalapril on insulin sensitivity in hypertensive patients. Am. J. Hypertens. 1999;12:298–303
  28. Anan F, Takahashi N, Ooie T, Hara M, Yoshimatsu H, Saikawa T. Candesartan, an angiotensin II receptor blocker, improves left ventricular hypertrophy and insulin resistance. Metabolism. 2004;53:777–781
  29. Takami T, Shigemasa M. Efficacy of various antihypertensive agents as evaluated by indices of vascular stiffness in elderly hypertensive patients. Hypertens. Res. 2003;26:609–614
  30. Munakata M, Nagasaki A, Nunokawa T, Sakuma T, Kato H, Yoshinaga K, et al. Effects of valsartan and nifedipine coat-core on systemic arterial stiffness in hypertensive patients. Am. J. Hypertens. 2004;17:1050–1055
  31. Anan F, Takahashi N, Ooie T, Yufu K, Hara M, Nakagawa M, et al. Effects of valsartan and perindopril combination therapy on left ventricular hypertrophy and aortic arterial stiffness in patients with essential hypertension. Eur. J. Clin. Pharmcol. 2005;61:353–359
  32. Nakamura T, Ushiyama C, Shimada N, Hayashi K, Ebihara I, Koide H. Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary endothelin-1 and albumin excretion in diabetes patients. J. Diabetes Complications. 2000;14:250–254
  33. Shargorodsky M, Wainstein J, Gavish D, Leibovitz E, Matas Z, Zimlichman R. Treatment with rosiglitazone reduces hyperinsulinemia and improves arterial elasticity in patients with type 2 diabetes mellitus. Am. J. Hypertens. 2003;16:617–622
  34. Bianchi S, Bigazzi R, Baldari G, Sgherri G, Campese VM. Diurnal variations of blood pressure and microalbuminuria in essential hypertension. Am. J. Hypertens. 1994;7:23–29
  35. Anan F, Takahashi N, Ooie T, Yufu K, Saikawa T, Yoshimatsu H. Role of insulin resistance in nondipper essential hypertensive patients. Hypertens. Res. 2003;26:669–676
  36. Stramba-Badiale M, Fox KM, Priori SG, Collins P, Daly C, Graham I, et al. Cardiovascular disease in women: a statement from the policy conference of the European Society of Cardiology. Eur. Heart J. 2006;27:994–1005

PII: S0168-8227(07)00047-2

doi: 10.1016/j.diabres.2007.01.009

Diabetes Research and Clinical Practice
Volume 77, Issue 3 , Pages 414-419 , September 2007

Article Tools

* Image Usage & Resolution